Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
University of Eastern Finland · Kuopio University Hospital
Abstract
There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established.
To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain.
Citation impact
- FWCI
- 26.42
- Percentile
- 100%
- References
- 29
Authors
7- TTTero TapiolaCorresponding
University of Eastern Finland
- IAIrina Alafuzoff
University of Eastern Finland, Kuopio University Hospital
- SHSanna‐Kaisa Herukka
University of Eastern Finland, Kuopio University Hospital
- LPLaura Parkkinen
University of Eastern Finland, Kuopio University Hospital
- PHPäivi Hartikainen
University of Eastern Finland, Kuopio University Hospital
Topics & keywords
- Cerebrospinal fluid
- Pathology
- Senile plaques
- Tau protein
- Medicine
- Alzheimer's disease
- Neurology
- Biomarker
- Good health and well-being